September 11, 2024 — In every way we look at this study, it is a remarkable milestone. With a randomized, controlled trial, Claudia Fox and colleagues have shown that a GLP-1, liraglutide, is effective for obesity in children as young as six years of age. In this year-long study, children who received liraglutide for obesity reduced their body mass […]
September 10, 2024 — Consumer spending is by far the biggest driver of U.S. economic growth. So you can be sure that businesses are paying close attention to the disruption in longstanding consumer behavior patterns that GLP-1 medicines are bringing. People are buying new clothes, better food, spending less on weight watching, and more on health. Make no mistake. […]
September 9, 2024 — The American College of Clinical Pharmacology is meeting in Bethesda this week. On the opening day, ACCP convened a symposium to address critical questions about how drugs work in people with obesity. What can we – industry, FDA, and scientists – do better? Because all too often, drug labels to guide safe prescribing are effectively […]
September 8, 2024 — What’s the harm? For many “interventions” to reduce obesity prevalence, this rationale seems to be good enough to spur implementation. Menu labeling is a good example. Restaurants in the U.S. and in numerous other places must publish the number of calories in food portions they sell. This went into effect based upon suppositions. Policy makers […]
September 7, 2024 — Recently, Novo Nordisk CEO Lars Fruergaard Jørgensen did a rare interview with NBC News to talk about the high price of obesity medicines that are proving to be so important for so many people. It seemed like a dress rehearsal for his coming appearance at a Senate hearing on the subject. He brought up the […]
September 6, 2024 — Think about it. Profound change is coming to healthcare and health systems because of the imperative for obesity care at scale. Right now, we are seeing only a faint glimmer of the changes that lie ahead. That’s because the biggest struggles with this change are very basic. Lilly and Novo Nordisk are straining to produce […]
September 4, 2024 — If nothing else, the ESC (European for Cardiology) Congress in London this week made one thing clear – everyone in mainstream medicine is now ready to claim the disease of obesity. Cardiologists all over the world are adopting a view we’ve been espousing here for decades. Obesity is not a lifestyle. Not a behavioral problem. […]
September 3, 2024 — For decades, the Environmental Protection Agency has promoted the use of sludge from sewage treatment plants as fertilizer. It seemed like a good idea at the time. The sludge – known as biosolids in the fertilizer industry – is rich in nutrients that crops need. Plus, using biosolids for this purpose kept them out of […]
August 31, 2024 — This is a truly remarkable finding. In the middle of the SELECT study of semaglutide for preventing deaths in people with obesity and heart disease, the COVID-19 pandemic struck. So researchers nimbly adapted and began collecting data on COVID outcomes. They found a big surprise. People who got COVID-19 and were treated with semaglutide had […]
August 29, 2024 — It is a pain to sort through the errors that find their way into research publications. Even more painful is the experience of having to retract flawed publications. So when the Editor in Chief of Childhood Obesity retracted a fundamentally flawed, cluster-randomized trial, we see a reason to celebrate. Errors that involve clustering designs in […]
